Recent Updates
Recently added Catalysts

IMGN151

Phase 2

Gynecologic Cancers | Small molecule | Oncology |AbbVie Inc.|Last Updated: Jun 2, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment377
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesPHASE2 RECRUITING 377Jul 30, 2025Feb 1, 2028Jun 2, 202616 United States, Israel +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Dose-limiting Toxicities (DLTs)
Up to approximately 3 years

Dose limiting toxicities (DLTs) of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

Percentage of Participants with Adverse Events (AE)
Up to approximately 3 years

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

Secondary Endpoints
Objective Response (OR)
Up to approximately 3 years
Duration of response (DOR)
Up to approximately 3 years
Progression-free survival (PFS)
Up to approximately 3 years
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm A: IMGN151 + Carboplatin (For PSOC)EXPERIMENTALParticipants will receive IMGN151 in combination with Carboplatin on Day 1 of a 21-day cycle.
Arm B: IMGN151 + Olaparib (For PSOC)EXPERIMENTALParticipants will receive IMGN151 in combination with Olaparib twice a day (BID) on Day 1 of a 21-day cycle.
Arm C: IMGN151 + Bevacizumab (For PSOC or PROC)EXPERIMENTALParticipants will receive IMGN151 in combination with Bevacizumab Day 1 of a 21-day cycle.
Arm D: IMGN151 Monotherapy (For PSOC)EXPERIMENTALParticipants will receive IMGN151 Day 1 of a 21-day cycle.
Arm E: IMGN151 Monotherapy (For PROC in China)EXPERIMENTALParticipants will receive IMGN151 Day 1 of a 21-day cycle.
Arm F: IMGN151 Monotherapy (For PROC in Japan)EXPERIMENTALParticipants will receive IMGN151 Day 1 of a 21-day cycle.
Interventions
NameTypeDescription
IMGN151DRUGIntravenous (IV) infusion
CarboplatinDRUGIntravenous (IV) infusion
BevacizumabDRUGIntravenous (IV) infusion
OlaparibDRUGOral Tablet
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexFEMALE
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * ECOG performance status of 0 or 1 * Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression after platinum combination standard of care therapy in Arms B and D) will have ≥ 1 lesion that...

Countries:United StatesIsraelJapan
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 2, 2026NCT07024784lastUpdatePostDate: changed
LOWJun 2, 2026NCT07024784lastUpdatePostDate: changed
LOWJun 2, 2026NCT07024784lastUpdatePostDate: changed
LOWMay 29, 2026NCT07024784lastUpdatePostDate: changed
LOWMay 29, 2026NCT07024784lastUpdatePostDate: changed
LOWMay 29, 2026NCT07024784lastUpdatePostDate: changed
LOWMay 26, 2026NCT07024784primaryCompletionDate: changed
LOWMay 24, 2026NCT07024784studyFirstPostDate: changed